A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Colleen Annesley, MD
Seattle Children's Hospital
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Children'S and Women'S Health Centre of British Columbia
Vancouver, British Columbia, Canada
- Children'S Hospital Los Angeles
Los Angeles, California, United States
- Children'S National Medical Center
Washington D.C., District of Columbia, United States
- Riley Hospital for Children
Indianapolis, Indiana, United States
- Seattle Children'S Hospital
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Nov 2017
- Primary completion
- 13 Sept 2023
- Completion
- 3 Mar 2035
- Last update posted
- 15 Dec 2025
- Registered enrollment
- 78
- Registry id
- NCT03330691
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.